Research evidence glossary: from cell studies to finished-product claims
Research findings apply first to the material, model, population and conditions actually studied. A cell study does not establish a human outcome, and a clinical trial of one formulation does not validate a supplier's research vial or blend. Start by identifying the study type and the exact material tested.
Identify the study type
| Term | Meaning | Question to carry forward |
|---|---|---|
| In vitro | Experiments outside a whole living organism, such as a cell-based system. | Does the model address my laboratory question? |
| In vivo | Experiments in a living organism; the term alone does not mean human. | Which species and experimental conditions were used? |
| Preclinical | Research before clinical testing, including relevant laboratory and animal studies. | What remains untested in people? |
| Clinical | Research involving people under a defined study plan. | Which population, formulation, comparator and outcomes were studied? |
Separate mechanisms, markers and outcomes
A mechanism describes how a biological process may work. A biomarker is a measured characteristic that can indicate a biological state or response. An endpoint is a defined study outcome.
A surrogate endpoint stands in for a clinical outcome; its interpretation depends on evidence that it predicts that outcome in the relevant setting. A change in receptor signalling, gene expression or a circulating marker should not automatically become a claim that people feel better, function better or live longer.
Read the design behind the result
Check the number and type of participants or experimental units, control group, study duration, measured outcomes and analysis plan. In a clinical paper, a phase number helps describe the development stage; it does not replace reading the actual protocol and results.
Look for the magnitude of the reported difference and the stated limitations. Do not summarize an exploratory observation as an established result across all populations or conditions.
Match the studied material to the claim
This comparison is an interpretive safeguard: evidence about a named ingredient is not direct evidence about a different finished product. Papers on separate components do not establish the behaviour of their mixture. Evidence about a full-length peptide should not automatically be applied to a shorter fragment.
| Comparison | Check in the paper and specification |
|---|---|
| Identity | Exact compound, sequence, modifications and molecular form. |
| Formulation | Single ingredient or blend, and the components actually studied. |
| Context | Cell model, animal species or human population. |
| Conclusion | What was measured and what the authors did not establish. |
How to read FSD's research references
Product references describe research on compounds or related materials. They do not verify the identity, quantity, purity or storage history of a purchased vial; those questions need relevant analytical and supply records.
For blends such as GLOW or KLOW, distinguish the listed supplier formula from a measured batch result, and component studies from studies of the finished blend. Materials remain intended for laboratory research, not human or veterinary administration.
Common questions
Does a clinical study validate a research vial with the same ingredient name?
No. The study's material and formulation must be considered. A shared name does not demonstrate that a supplier's vial matches the clinical product or carries the same evidence.
Do studies of each ingredient prove that a blend has a combined effect?
No. Separate ingredient studies do not directly test the mixture. A combined claim needs evidence for the relevant blend and conditions.
Can a COA demonstrate that a product works biologically?
A COA supports only the tests it reports. Chemical identity, purity and quantity are not demonstrations of a research outcome or therapeutic effect.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- Step 2: Preclinical Research — FDA
Preclinical research includes in vitro and in vivo studies and precedes decisions about testing in people. - Step 3: Clinical Research — FDA
Clinical studies involve people, defined protocols, populations, comparators, assessments and trial phases. - FDA Facts: Biomarkers and Surrogate Endpoints — FDA
Biomarkers, clinical outcomes and surrogate endpoints are distinct; changes in a marker do not by themselves establish overall benefit and risk.